Amneal Sustainability Profile
Amneal Pharmaceuticals, a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2002, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals. With a strong operational presence across North America and beyond, Amneal focuses on delivering high-quality, affordable medications that cater to a diverse range of therapeutic areas. The company’s core offerings include a wide array of generic drugs, specialty products, and over-the-counter medications, distinguished by their commitment to quality and innovation. Amneal has achieved significant milestones, including strategic partnerships and a robust pipeline of products, positioning itself as a trusted name in the market. With a dedication to improving patient access to essential medications, Amneal Pharmaceuticals continues to make a meaningful impact in the healthcare landscape.
DitchCarbon Score
How does Amneal's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amneal's score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amneal's reported carbon emissions
Amneal Pharmaceuticals, headquartered in the US, currently does not provide specific carbon emissions data for the most recent year, as no emissions figures are available. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In terms of climate commitments, Amneal has not outlined any specific reduction targets or initiatives, nor have they made any pledges related to climate action. The absence of data and commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly focuses on sustainability, Amneal's lack of publicly available emissions data and climate initiatives may place it at a disadvantage compared to competitors who are actively pursuing measurable reduction targets and transparent reporting.
How Carbon Intensive is Amneal's Industry?
How Carbon Intensive is Amneal's Location?
Amneal's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Amneal has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
